King Luther Capital Management Corp Purchases 28,981 Shares of Abbott Laboratories $ABT

King Luther Capital Management Corp boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,464,440 shares of the healthcare product maker’s stock after acquiring an additional 28,981 shares during the quarter. King Luther Capital Management Corp’s holdings in Abbott Laboratories were worth $183,480,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. Capital International Investors boosted its holdings in Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares in the last quarter. Invesco Ltd. boosted its holdings in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares in the last quarter. Ameriprise Financial Inc. increased its position in Abbott Laboratories by 3.8% during the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock worth $1,804,050,000 after buying an additional 499,351 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in Abbott Laboratories by 7.2% during the third quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock valued at $1,727,869,000 after buying an additional 864,531 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last 90 days. 0.46% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. BTIG Research reiterated a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a research note on Monday, April 27th. Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Royal Bank Of Canada decreased their target price on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research report on Wednesday, April 22nd. Finally, Oppenheimer reduced their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.43.

Abbott Laboratories Trading Down 1.0%

Abbott Laboratories stock opened at $86.50 on Wednesday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market capitalization of $150.67 billion, a PE ratio of 24.23, a PEG ratio of 1.46 and a beta of 0.65. The business’s 50-day simple moving average is $95.89 and its 200-day simple moving average is $111.43.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.